Myocarditis: causes, symptoms, diagnosis and treatment

Let’s talk about myocarditis: ‘Cardiomyopathy’ is a general term for the primary disease of the heart muscle (myocardium)

Myocarditis: myocardial damage from coronary artery disease and hypertension is responsible for the vast majority of heart diseases

In this section of the site, we will discuss myocardial diseases of non-ischaemic and non-hypertensive origin, which are responsible for approximately 5-10 of cases of heart failure.

This group includes:

  • dilated cardiomyopathy
  • hypertrophic cardiomyopathy;
  • restrictive cardiomyopathy;
  • alcoholic cardiomyopathy;
  • arrhythmogenic right ventricular cardiomyopathy;
  • myocarditis.


Myocarditis is a self-limiting inflammatory disease of the myocardium, the heart muscle, but – occasionally – life-threatening and capable of affecting individuals of any age.

Inflammation of the myocardium can have many causes, but frequently occurs as a consequence of viral infections, often caused by Coxsackievirus, Cytomegalovirus, Hepatitis C virus, Herpes virus, HIV, Adenovirus, Parvovirus: in this case one speaks of ‘viral myocarditis’ occurring during active virus replication in the myocardium or in the subsequent auto-immune phase of the disease.

The expression post-viral myocarditis has also been used to specifically describe the autoimmune phase.

When neither a direct aetiological relationship nor a specific cause can be established, it is more widely accepted to use the expression lymphocytic myocarditis to indicate this predominant histological feature in affected individuals.

In the United States, an estimated 25 per cent of the 750,000 heart failure patients present with DCM, accounting for 50 per cent of heart transplant patients.

Although DCM has multiple causes, viral infection plays a key role in its pathogenesis and is responsible for 21% of DCM cases over an average follow-up of 33 months.

In military recruits and adults under 40 years of age, epidemiological studies have calculated that viral myocarditis is an aetiological factor in 20% of sudden death cases.

Histological evidence of myocarditis is routinely observed in 1-9% of autopsy examinations.

Causes of myocarditis

As already mentioned, viral infection is responsible for the majority of myocarditis cases in industrialised societies.

Enteroviruses such as Coxsackie B are non-enveloped RNA viruses of the picornavirus family.

The B group of coxsackieviruses, in particular subtypes B3 and B4, and adenoviruses are high on the list of human pathogens.

The coxsackieviruses are distinguished from the other picornavirus types on the basis of their pathogenesis in susceptible host organisms and antigenic classifications.

These main classes are coxsackievirus group A (Al to A22, A24) and coxsackievirus group B (B1 to B6).

Group A coxsackieviruses after inoculation in infant mice produce myositis and generalised paralysis.

Group B coxsackieviruses produce distinct focal muscle lesions, necrosis of interscapular fat pads, brain damage and spastic paralysis.

Improvements in molecular detection have made it possible to implicate other viruses, such as hepatitis C viruses and human cytomegalovirus (CMV), alone or in combination with cardiotropic agents such as HIV.

HIV has emerged as one of the main aetiological agents of DCM of viral origin.

In patients who are HIV-positive, cardiac decompensation with lymphocytic interstitial myocardiosis is a frequent complication, with an estimated prevalence of between 8 per cent and 50 per cent or more.

The precise mechanism of HIV-induced heart disease has been debated, but available scientific evidence suggests that HIV shows cardiotropism.

Among patients with active Acquired ImmunoDeficiency Syndrome (AIDS), myocarditis and other viral, protozoal and bacterial infections are commonly observed, indicating that these concomitant diseases and autoimmunity may be contributing factors to HIV-induced myocarditis Non-viral infectious agents may also cause myocarditis.

In Central and South America, infection with the protozoan Trypanosoma cruzi (Chagas disease) is the main cause of myocarditis

This parasitic infection is largely immune-mediated so treatment with anti-protozoal therapy with nifurtimox or benzimidazole is beneficial.

Likewise, diphtheria myocarditis has been reported in 22% of patients with a lethality rate of 3%.

Combination therapy with diphtheria antitoxin and antibiotics is usually effective.

Bacterial infections, toxoplasmosis or infection with tick bite spirochetes, Borrelia burgdorferi (Lyme disease) are also known to be causes of myocarditis.

Although no definite cause of peripartum cardiomyopathy has been found, lymphocytic infiltration has been discovered in up to 50 per cent of myocardial biopsy specimens, suggesting the presence of an autoimmune process or enhanced susceptibility to viral myocarditis.

Finally, numerous non-infectious causes of myocarditis are well documented and include pharmacological agents, drugs, systemic inflammatory disorders and granulomatous diseases.


Symptoms and signs of myocarditis may include:

  • dyspnoea (difficulty breathing);
  • oedema in the lower limbs (swelling of the legs);
  • tightness in the chest;
  • chest pain (similar to that of a myocardial infarction);
  • pain in the upper abdomen;
  • palpitations and arrhythmias (irregular heartbeat);
  • tachycardia (increased heart rate);
  • asthenia (tiredness);
  • easy fatigability even with mild exertion;
  • fever;
  • fainting;
  • flu-like symptoms (such as sore throat and headache).

Diagnosis of myocarditis

On objective examination, the clinical features of inflammatory myocarditis vary widely.

The hypothesis of viral myocarditis may be considered when patients are seen after a recent febrile illness followed by the onset of cardiac symptoms such as dyspnoea, asthenia, chest pain or arrhythmic palpitations.

Others may present with conduction system abnormalities, acute congestive heart failure or an embolic event originating from intracardiac thrombi.

After the initial insult, several days may pass before any of the cardiac symptoms manifest themselves.

On objective examination, the patient is often tachycardic.

In severe cases, typical signs of congestive heart failure are distended jugular veins, pulmonary rales, peripheral oedema, hepatomegaly and S3 gallop rhythm on cardiac examination.

If pericardial inflammation is present, friction may be appreciated.

Elevated cardiac enzymes and increased viral titres confirm the diagnosis.

Although there are no pathognomonic findings of myocarditis on electrocardiogram, sinus tachycardia and non-specific ST segment and T wave abnormalities are common.

With pericardial involvement, ECG findings typical of acute pericarditis are observed, including diffuse ST-segment elevation.

Electrophysiological complications may include arrhythmias, conduction defects or cardiac arrest; sudden death caused by ventricular fibrillation has also been described.

Echocardiography is used to confirm the severity of systolic ventricular dysfunction and, in some cases, produces qualitative changes in image brightness indicative of myocarditis, however, MRI is a powerful diagnostic tool with high sensitivity and specificity in the non-invasive assessment of suspected viral myocarditis due to advances in tissue characterisation of the myocardium.


The use of transvenous endomyocardial biopsy, first introduced in 1962, facilitates the diagnosis and treatment of myocarditis in antemortem specimens

Although we have long relied on histomorphological abnormalities observed under the light microscope, the so-called Dallas criteria, many pathologists and clinicians have now abandoned these arbitrary clinicopathological classifications because of the wide intra- and inter-observer variability.

Histomorphological abnormalities that confirm this classification of DCM include interstitial fibrosis, myocyte degeneration and increased reparative fibrosis of the extracellular matrix.

A faster diagnosis of myocarditis is now possible by applying polymerase chain reaction (PCR) to detect specific viral genomes in the myocardium.

When biopsy is guided by imaging techniques such as MRI, an increase in sensitivity and specificity of this diagnostic tool has been described in a limited number of studies.

According to the available scientific literature, the indications for endomyocardial biopsy are:

  • make the diagnosis of hypothesised myocarditis in a patient with new onset heart failure,
  • to consider alternative diagnoses (e.g. giant cell myocarditis) in patients who are not responsive to conventional heart failure therapy
  • monitor response after immunosuppressive therapy if clinically indicated (e.g. relapse or disease progression),
  • decide on the implantation of a permanent pacemaker when the cause is an inflammatory process.

Both the sensitivity and specificity of endomyocardial biopsy are reduced when the viral infection is focal, remote or subclinical.

In the paediatric population, a viral aetiology is a frequent diagnosis for new-onset heart failure and/or cardiogenic shock.

In adults, viral myocarditis presents more insidiously and, without a high index of clinical suspicion, may be misdiagnosed as heart failure secondary to ischaemic heart disease, diabetes, hypertension or cardiac valvulopathy.

For new-onset heart failure lasting less than three months, idiopathic Giant Cell Myocarditis (IGCM) must be considered in patients who do not respond to conventional heart failure therapy.

Endomyocardial biopsy with histological evidence of diffuse inflammatory lymphocytic infiltrate and myocytic necrosis interspersed with eosinophils and multinucleated giant cells is required to make the diagnosis.

Immunosuppressive therapy has been used for IGCM, but no published studies have established its benefit.

New insights into the molecular mechanisms related to the different stages of the disease, from viral infection to cardiac remodelling, suggest the need to re-evaluate existing practices for the diagnosis and treatment of viral myocarditis.

Early disease may escape clinical recognition because viral replication may be entirely asymptomatic and go undetected without myocardial sequelae

Complete recovery with an excellent prognosis can be expected in most cases of uncomplicated myocarditis.

In infants, the development of myocarditis, often due to epidemics in the nursery or from infected mothers, may progress into multisystem disease affecting the liver and central nervous system.

Clinical signs such as difficulty in feeding, lethargy and fever are preceded by either cardiac or respiratory distress syndrome, or both.

The initial infection with myocardial involvement sets the stage for the multiple stages of myocarditis with increased risk of re-infection and autoimmune reactivation of the disease.

Elderly patients typically seek medical care for the management of congestive heart failure and possibly DCM.

Negative prognostic factors

In patients with DCM, risk factors for sudden death are a positive signal-averaged ECG, a low heart rate variability index, ventricular tachycardia or inducible fibrillation, non-sustained ventricular tachycardia and left ventricular dysfunction.

Therapy in cases of myocarditis

To date, no effective therapy has been outlined for viral myocarditis.

Clinical trials for immunosuppressive therapy have not demonstrated clinical efficacy.

Empirical trials in which specific antiviral agents are administered according to genomic diagnosis lack long-term follow-up of clinical outcomes.

Treatment of myocardial heart failure follows established clinical therapy and includes diuretics, alpha-adrenergic blockers, ACE inhibitors and aldosterone antagonists.

Patients with probable or definite evidence of myocarditis must withdraw from all competitive sports activities and undergo a period of convalescence for at least 6 months after the onset of clinical manifestations.

Athletes may return to training and competition after this time if cardiac function and size return to normal, clinically relevant arrhythmias are absent, and serum markers of inflammation and heart failure have normalised.

Read Also:

Emergency Live Even More…Live: Download The New Free App Of Your Newspaper For IOS And Android

Surgery Of Myocardial Infarction Complications And Patient Follow-Up

Heart Disease: What Is Cardiomyopathy?

Inflammations Of The Heart: Myocarditis, Infective Endocarditis And Pericarditis

Heart Murmurs: What It Is And When To Be Concerned

Broken Heart Syndrome Is On The Rise: We Know Takotsubo Cardiomyopathy

What Is A Cardioverter? Implantable Defibrillator Overview

Tachycardia: Is There A Risk Of Arrhythmia? What Differences Exist Between The Two?

Bacterial Endocarditis: Prophylaxis In Children And Adults

Erectile Dysfunction And Cardiovascular Problems: What Is The Link?

Early Management Of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment, Updating In AHA 2015 Guidelines

Precordial Chest Punch: Meaning, When To Do It, Guidelines

First Aid In The Event Of An Overdose: Calling An Ambulance, What To Do While Waiting For The Rescuers?

Cardiomyopathies: What They Are And What Are The Treatments


Medicina Online

You might also like